Sunday, 4 October 2026European Markets

CRCAM PARIS ET IDF And PEUGEOT INVEST Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - crcam paris et idf (caf.pa) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
crcam paris et idf (caf.pa) €67.08 4.41% 5.07%
peugeot invest (peug.pa) €107.80 2.63% 4.8%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. crcam paris et idf (caf.pa)

4.41% forward dividend yield and 5.07% return on equity

caisse régionale de crédit agricole mutuel de paris et d'ile-de-france, a cooperative bank, provides banking services to its members in france. it offers saving products; accounts and cards; vehicle and home financing; finance for study and work; and insurance products to protect home, vehicle, and health. the company is based in paris, france. caisse régionale de crédit agricole mutuel de paris et d'ile-de-france operates as a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam paris et idf has a trailing twelve months eps of €13.24.

pe ratio

crcam paris et idf has a trailing twelve months price to earnings ratio of 5.07. meaning, the purchaser of the share is investing €5.07 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.07%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, crcam paris et idf's stock is considered to be overbought (>=80).

moving average

crcam paris et idf's value is under its 50-day moving average of €71.63 and under its 200-day moving average of €71.26.

volume

today's last reported volume for crcam paris et idf is 417 which is 9.54% below its average volume of 461.

yearly top and bottom value

crcam paris et idf's stock is valued at €67.08 at 17:30 est, way under its 52-week high of €77.00 and higher than its 52-week low of €64.06.

more news about crcam paris et idf.

2. peugeot invest (peug.pa)

2.63% forward dividend yield and 4.8% return on equity

peugeot invest société anonyme operates as an investment company. the firm invests in private equity and real estate funds. the firm also invests in governance, social, and environmental protection. the company was formerly known as ffp société anonyme and changed its name to peugeot invest société anonyme. peugeot invest société anonyme was incorporated in 1929 and is headquartered in paris, france.

earnings per share

as for profitability, peugeot invest has a trailing twelve months eps of €9.4.

pe ratio

peugeot invest has a trailing twelve months price to earnings ratio of 11.47. meaning, the purchaser of the share is investing €11.47 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.8%.

volume

today's last reported volume for peugeot invest is 1618 which is 71.69% below its average volume of 5716.

volatility

peugeot invest's last week, last month's, and last quarter's current intraday variation average was a negative 0.24%, a negative 0.07%, and a positive 1.36%.

peugeot invest's highest amplitude of average volatility was 1.07% (last week), 1.12% (last month), and 1.36% (last quarter).

sales growth

peugeot invest's sales growth for the current quarter is negative 15.4%.

dividend yield

according to morningstar, inc., the next dividend payment is on may 18, 2023, the estimated forward annual dividend rate is 2.85 and the estimated forward annual dividend yield is 2.63%.

more news about peugeot invest.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com